Navigation Links
Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab

Merck Pharmaceuticals from Germany and Takeda Pharmaceuticals from Japan to colloborate in marketing of Merck's cancer drug Matuzumab.

Matuzumab is developed by Merck which is in its Phase II // clinical tiral. Takeda Pharmaceuticals will sign agreement with Merck to give royalty and sale benefits from the sale of Matuzumba. Takeda will pay 60 million euros to Merck with an addition of royalty.

"Merck KGaA and Takeda Pharmaceutical have entered into a co-development and co-commercialization agreement for Merck's Matuzumab," the German company said in a statement.

Matuzumab was developed by Merck and currently is in Phase II clinical trials in patients with lung, gastric and colorectal cancers. Merck said it had decided to enter into cooperation with Takeda "in order to put more resources and expertise toward this important product". "Takedas experience and commitment in the field of oncology makes it a perfect fit with Merck, " it said.

"This collaboration with Takeda, Japans largest pharmaceutical company, will allow us to move ahead quickly with development and commercialisation of this potentially important product for cancer patients," said the head of Merck Ethical Pharmaceuticals, Elmar Schnee.

Source: Indo-Asian News Services
'"/>




Page: 1

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Judgment In Favor Of Merck For Vioxx Drug
4. Merck, ICMR to conduct joint trials on cervical cancer vaccine
5. Merck in the Dock Due To Vioxx
6. Merck Says Januvia Effective In Type 2 Diabetes
7. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
8. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
9. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
10. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
11. Ranbaxy in Fray to Buy Mercks Generic Drugs Unit
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association ... restaurants, launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 ... ALS and related diseases that severely limit strength and mobility. , Now ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... George H. Van Allen have signed a joint enrollment and degree completion agreement. ... pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows ...
(Date:2/5/2016)... ... , ... US Sports Camps , official operators of Nike Yoga Camps, ... yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New England city ... Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Global Immunology Market to 2022 - ... market growth Summary Immune-mediated inflammatory diseases ... that affect 5–7% of western populations. Although they ... and key patient demographics, they are pathophysiologically linked, ... an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology: